<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
<ArticleSet>
<Article>
<Journal>
<PublisherName>journal-jmsr</PublisherName>
<JournalTitle>Journal of Medical and Surgical Research</JournalTitle>
<PISSN>I</PISSN>
<EISSN>S</EISSN>
<Volume-Issue>Vol. I, n 1 </Volume-Issue>
<PartNumber/>
<IssueTopic>Multidisciplinary</IssueTopic>
<IssueLanguage>English</IssueLanguage>
<Season>June, 2014</Season>
<SpecialIssue>N</SpecialIssue>
<SupplementaryIssue>N</SupplementaryIssue>
<IssueOA>Y</IssueOA>
<PubDate>
<Year>-0001</Year>
<Month>11</Month>
<Day>30</Day>
</PubDate>
<ArticleType>JMSR Oncology</ArticleType>
<ArticleTitle>Bilateral MALT (Mucosal Associated Lymphoid Tissue) Lymphoma of the Conjunctiva. A Rare Case Report</ArticleTitle>
<SubTitle/>
<ArticleLanguage>English</ArticleLanguage>
<ArticleOA>Y</ArticleOA>
<FirstPage>22</FirstPage>
<LastPage>23</LastPage>
<AuthorList>
<Author>
<FirstName>N. Alami</FirstName>
<LastName>Drideb</LastName>
<AuthorLanguage>English</AuthorLanguage>
<Affiliation/>
<CorrespondingAuthor>N</CorrespondingAuthor>
<ORCID/>
<FirstName>H.</FirstName>
<LastName>Eddou</LastName>
<AuthorLanguage>English</AuthorLanguage>
<Affiliation/>
<CorrespondingAuthor>Y</CorrespondingAuthor>
<ORCID/>
<FirstName>K.</FirstName>
<LastName>Doghmi</LastName>
<AuthorLanguage>English</AuthorLanguage>
<Affiliation/>
<CorrespondingAuthor>Y</CorrespondingAuthor>
<ORCID/>
<FirstName>M.</FirstName>
<LastName>Mikdame</LastName>
<AuthorLanguage>English</AuthorLanguage>
<Affiliation/>
<CorrespondingAuthor>Y</CorrespondingAuthor>
<ORCID/>
</Author>
</AuthorList>
<DOI/>
<Abstract>MALT (Mucosal Associated Lymphoid Tissue) lymphomas of the conjunctiva belong to the extranodal marginal zone B-cell lymphomas. This site, while standard, is uncommon. We present the observation of a 65 year__ampersandsign#39;s old man who presented a pink papular tumor developed on both lower eyelids. The CT-scan showed thickeni ng of soft tissues associated with bilateral eyelid and sub diaphragmatic nodes. A chemotherapy protocol based on eight courses of R-CHOP was established with a complete remission. Twelve months later, another bilateral eylid swelling reappeared. Treatment with local radiotherapy to 24 Gy was proposed with good outcome 28 months later.</Abstract>
<AbstractLanguage>English</AbstractLanguage>
<Keywords>Conjunctiva, Lymphoma, MALT , Rituximab</Keywords>
<URLs>
<Abstract>https://www.journal-jmsr.net/ubijournal-v1copy/journals/abstract.php?article_id=4684&title=Bilateral MALT (Mucosal Associated Lymphoid Tissue) Lymphoma of the Conjunctiva. A Rare Case Report</Abstract>
</URLs>
<References>
<ReferencesarticleTitle>References</ReferencesarticleTitle>
<ReferencesfirstPage>16</ReferencesfirstPage>
<ReferenceslastPage>19</ReferenceslastPage>
<References>1. Benabid. L et al. Les lymphomes malins non hodgkiniens conjonctivo-orbitaires. J Fr. Ophtalmol., 2005; 28, 10, 1058-1064.
2. Mannami T and al. Clinical, histopathological, and immunogenetic analysis of ocular adnexal lymphoproliferative disorders: characterization of malt lymphoma and reactive lymphoid hyperplasia. Mod Pathol 2001;14:641-9.
3. Francesca Collina and al. Chlamydia psittaci in ocular adnexa MALT lymphoma: a possible role in lymphomagenesis and a different geographical distribution. Infectious Agents and Cancer 2012, 7:8.
4. Raderer M and al. Importance of extensive staging in patients with mucosa-associated lymphoid tissue (MALT)-type lymphoma. Br J Cancer 2000;83:454-7.
5. Gaucher D and al. MALT-type B-cell lymphoma masquerading as scleritis or posterior uveitis. J Fr Ophtalmol. 2005 Jan;28(1)
6. Voegtle R and al. MALT lymphoma of the lacrimal apparatus (mucosa-associated lymphoid tissue). J Fr Ophtalmol. 1999 Oct;22(8):884-7.
7. Benabid L et al. Nouvelle approche thand;eacute;rapeutique du lymphome malin non hodgkinien orbitaire : and;agrave; propos de deux cas traitand;eacute;s par rituximab. J Fr Ophtalmol, 2005;28:769-71.
8. Davies A and al. Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study. Lancet Oncol. 2014 Feb 7. pii: S1470-2045(14)70005-1</References>
</References>
</Journal>
</Article>
</ArticleSet>